Steven C Plaxe1. 1. Division of Gynecologic Oncology, Department of Reproductive Medicine, Rebecca and John Moores University of California, San Diego, Cancer Center, San Diego, CA, USA. splaxe@ucsd.edu
Abstract
OBJECTIVE: The objective of the study was to determine whether the epidemiology of low-grade ovarian serous cancers is distinct from that of high-grade ovarian serous cancers. STUDY DESIGN: The National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program reports incidence, and survival, data from representative population based cancer registries. The SEER data are analyzed to compare the descriptive epidemiologies of low- and high-grade lesions. RESULTS: Mean survival (99 vs 57 months) and age (55.5 vs 62.6 years) trends in annual incidence rate (-3.8% vs 1.4%), rate ratio of advanced to early disease (1.9 vs 10.2), rate ratio of post- to premenopausal incidence (5.0 vs 13.0). and difference in average age between advanced and early stage (none vs 2.5 years) are significantly different for patients with low-grade, compared with high-grade, disease. CONCLUSION: Epidemiology of low-grade tumors appears sufficiently different from that of high-grade lesions to support the concept that low-grade ovarian serous cancers constitute a distinct clinical, and perhaps biologic, entity.
OBJECTIVE: The objective of the study was to determine whether the epidemiology of low-grade ovarian serous cancers is distinct from that of high-grade ovarian serous cancers. STUDY DESIGN: The National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program reports incidence, and survival, data from representative population based cancer registries. The SEER data are analyzed to compare the descriptive epidemiologies of low- and high-grade lesions. RESULTS: Mean survival (99 vs 57 months) and age (55.5 vs 62.6 years) trends in annual incidence rate (-3.8% vs 1.4%), rate ratio of advanced to early disease (1.9 vs 10.2), rate ratio of post- to premenopausal incidence (5.0 vs 13.0). and difference in average age between advanced and early stage (none vs 2.5 years) are significantly different for patients with low-grade, compared with high-grade, disease. CONCLUSION: Epidemiology of low-grade tumors appears sufficiently different from that of high-grade lesions to support the concept that low-grade ovarian serous cancers constitute a distinct clinical, and perhaps biologic, entity.
Authors: Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen Journal: Gynecol Oncol Date: 2009-06-27 Impact factor: 5.482
Authors: Marta Llauradó Fernández; Gabriel E DiMattia; Amy Dawson; Sylvia Bamford; Shawn Anderson; Bryan T Hennessy; Michael S Anglesio; Trevor G Shepherd; Clara Salamanca; Josh Hoenisch; Anna Tinker; David G Huntsman; Mark S Carey Journal: Am J Cancer Res Date: 2016-10-01 Impact factor: 6.166
Authors: Rebecca Ann Previs; Joshua Kilgore; Renatta Craven; Gloria Broadwater; Sarah Bean; Sara Wobker; Megan DiFurio; Victoria Bae-Jump; Paola A Gehrig; Angeles Alvarez Secord Journal: Int J Gynecol Cancer Date: 2014-05 Impact factor: 3.437
Authors: Erin K Crane; Charlotte C Sun; Pedro T Ramirez; Kathleen M Schmeler; Anais Malpica; David M Gershenson Journal: Gynecol Oncol Date: 2014-11-08 Impact factor: 5.482
Authors: Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz Journal: Gynecol Oncol Date: 2009-06-06 Impact factor: 5.482